Skip to content
ClinCalc Pro
Menu
Topical Corticosteroid — Potent

Fluocinolone Acetonide (Topical)

Brand names: Synalar, Synalar N (with neomycin), Synalar C (with clotrimazole)

Topical fluocinolone acetonide is a potent synthetic corticosteroid applied to the skin for inflammatory and pruritic dermatoses such as eczema and psoriasis that are unresponsive to milder steroids.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds intracellular glucocorticoid receptors to suppress release of inflammatory mediators, producing local anti-inflammatory, vasoconstrictive and antiproliferative effects in the skin.

Prescribing in practice

  • As a potent topical steroid, prolonged or extensive use—especially under occlusion, on the face/flexures, or in children—risks skin atrophy, striae and systemic absorption, so apply thinly to the smallest effective area for the shortest time.
  • Avoid use on untreated bacterial, fungal or viral skin infections unless combined with appropriate antimicrobial cover.
  • Step down to a less potent preparation once the flare is controlled and review continued need.

Monitoring

Monitor the treated skin for signs of atrophy, telangiectasia or worsening infection, and reassess if there is no improvement within the expected period.

Counselling the patient

  • Apply a thin layer only to the affected areas and wash hands afterwards unless the hands are being treated.
  • Do not use on the face or skin folds for prolonged periods unless specifically advised.
  • Continue any prescribed emollients, separating their application from the steroid.

Evidence & guidelines

Use of topical corticosteroids by potency and quantity (fingertip units) follows established NICE and MHRA guidance on safe topical steroid use.

Reference: BAD Topical Corticosteroid Guidelines; MHRA Drug Safety Update (2021); NICE NG10 (Psoriasis); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.